Briacell Therapeutics Corp Stock Price, News & Analysis

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced a 1-for-10 share consolidation to maintain Nasdaq listing compliance. The consolidation is expected to take effect on August 25, 2025, with post-consolidation trading beginning around August 26, 2025, subject to TSX and Nasdaq approval.

Under the consolidation terms, shareholders will receive one new share for every ten existing shares. Fractional shares will be handled by rounding up fractions of ½ or greater to one whole share, while smaller fractions will be cancelled. The company's convertible securities will be proportionally adjusted, and trading symbols will remain unchanged on both exchanges.

BriaCell Therapeutics (NASDAQ: BCTX) has announced the addition of UCLA Health Jonsson Comprehensive Cancer Center as a key site for its pivotal Phase 3 clinical study (Bria-ABC). The study evaluates Bria-IMT™ combined with a checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer patients.

The trial's interim analysis will be conducted after 144 patient events, with overall survival as the primary endpoint. Building on positive Phase 2 survival data presented at ASCO 2025, the study has received FDA Fast Track designation. BriaCell expects to share top-line data in 2026.

BriaCell Therapeutics (NASDAQ: BCTX) has secured New Zealand Patent No. 785587 for its whole-cell cancer immunotherapy technology. The patent, valid through February 27, 2037, covers methods for selecting cancer immunotherapy based on HLA allele profile matching.

This development strengthens BriaCell's precision medicine approach, focusing on personalizing immunotherapy for enhanced patient outcomes. The patent is part of the company's broader strategy to build a robust international patent portfolio for global development and commercialization across multiple cancer indications.

BriaCell Therapeutics (NASDAQ: BCTX) and its subsidiary BriaPro have announced the filing of a patent application for their novel TILsRx immunotherapy platform. The platform is designed to develop multivalent agents that can simultaneously target multiple cancer-associated and immune pathway targets.

The technology focuses on activating tumor-infiltrating lymphocytes (TILs) and includes key components such as soluble CD80, anti-CD3, IL-21, and anti-STEAP1. An early candidate target is B7-H3, which is overexpressed in multiple cancers including prostate, lung, breast, pancreatic, and ovarian cancer.

The platform aims to provide improved clinical responses while minimizing off-target toxicity, with the flexibility to incorporate new immunotherapy targets as they are identified.

BriaCell Therapeutics (NASDAQ: BCTX) has announced two clinical data poster presentations at the upcoming ESMO Congress 2025 in Berlin, Germany. The presentations will focus on the company's Phase III pivotal trial of Bria-IMT combined with CPI for advanced metastatic breast cancer treatment.

The two posters (#8212 and #3928) will present data on the BRIA-ABC trial, examining both the pivotal trial results and the feasibility and biomarker validation aspects of this international randomized Phase 3 study. The abstracts will be published on the ESMO website on October 13th, 2025, with the congress taking place from October 17-21, 2025.

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company focused on immunotherapy for cancer care, has successfully closed a $15 million public offering. The offering consisted of 12 million units priced at $1.25 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.

The warrants are exercisable at $1.50 per share for a five-year period, while pre-funded warrants have an exercise price of $0.001. ThinkEquity served as the sole placement agent. The company plans to utilize the proceeds for working capital, general corporate purposes, and advancing its business objectives.

BriaCell Therapeutics (NASDAQ: BCTX), a clinical-stage biotechnology company, has announced the pricing of a $15 million public offering. The offering consists of 12 million units priced at $1.25 per unit, with each unit comprising one common share (or pre-funded warrant) and one warrant.

The warrants are immediately exercisable at $1.50 per share with a five-year expiration term. ThinkEquity is serving as the sole placement agent, and the offering is expected to close on July 16, 2025. The company plans to use the proceeds for working capital, general corporate purposes, and advancing business objectives.

BriaCell Therapeutics (NASDAQ: BCTX) has announced the addition of Mayo Clinic as a clinical site for its pivotal Phase 3 study in metastatic breast cancer. The study now encompasses 69 active clinical sites across 15 states.

The Phase 3 trial is evaluating Bria-IMT™ plus immune checkpoint inhibitor versus physician's choice in advanced metastatic breast cancer. The study's primary endpoint will analyze interim data after 144 patient events (deaths), comparing overall survival between treatment groups. The company recently reported positive Phase 2 survival data at ASCO 2025, and the Bria-IMT combination regimen has received FDA Fast Track designation.

BriaCell Therapeutics (NASDAQ: BCTX) has reported promising Phase 2 survival data for its Bria-IMT™ immunotherapy in combination with checkpoint inhibitors for metastatic breast cancer treatment. The study showed significant survival advantages over Trodelvy® and control groups:

In triple negative breast cancer (TNBC), Bria-IMT achieved median overall survival of 13.9 months, surpassing Trodelvy (11.8 months) and doubling control group (6.9 months). For hormone receptor positive (HR+) patients, Bria-IMT reached 17.3 months median survival versus Trodelvy's 14.4 months and control's 11.2 months.

The Phase 2 study included 54 heavily pre-treated patients who had received a median of 6 prior therapies. Notably, no Bria-IMT related treatment discontinuations were reported, and the company is currently conducting a pivotal Phase 3 study.